Shanghavie Loganathan

Shanghavie Loganathan

Auto-generated profile, based on publicly available information

Shanghavie Loganathan

University of Oxford

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
NRNader Raafat
Nader Raafat
SLShanghavie Loganathan
Shanghavie Loganathan
MMMavuto Mukaka
Mavuto Mukaka
Stuart D BlacksellStuart D Blacksell
Stuart D Blacksell
Richard MaudeRichard Maude
Richard Maude
Background: Dengue is the world’s most common mosquito-borne virus but remains diagnostically challenging due to its nonspecific presentation. Access to laboratory confirmation is limited and thus most reported figures are based on clinical diagnosis alone, the accuracy of which is uncertain. This systematic review assesses the diagnostic accuracy of the traditional (1997) and revised (2009) WHO clinical case definitions for dengue fever, the basis for most national guidelines. Methodology/Principal findings: PubMed, EMBASE, Scopus, OpenGrey, and the annual Dengue Bulletin were searched for studies assessing the diagnostic accuracy of the unmodified clinical criteria. Two reviewers (NR/SL) independently assessed eligibility, extracted data, and evaluated risk of bias using a modified QUADAS-2. Additional records were found by citation network analysis. A meta-analysis was done using a bivariate mixed-effects regression model. Studies that modified criteria were analysed separately. This systematic review protocol was registered on PROSPERO (CRD42020165998). We identified 11 and 12 datasets assessing the 1997 and 2009 definition, respectively, and 6 using modified criteria. Sensitivity was 93% (95% CI: 77–98) and 93% (95% CI: 86–96) for the 1997 and 2009 definitions, respectively. Specificity was 29% (95% CI: 8–65) and 31% (95% CI: 18–48) for the 1997 and 2009 definitions, respectively. Diagnostic performance suffered at the extremes of age. No modification significantly improved accuracy. Conclusions/Significance: Diagnostic accuracy of clinical criteria is poor, with significant implications for surveillance and public health responses for dengue control. As the basis for most reported figures, this has relevance to policymakers planning resource allocation and researchers modelling transmission, particularly during COVID-19.

15 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
XCXin Hui S Chan
Xin Hui S Chan
IHIlsa L Haeusler
Ilsa L Haeusler
BCBennett J K Choy
Bennett J K Choy
ZHZakiul Hassan
Zakiul Hassan
JTJunko Takata
Junko Takata
POPiero Olliaro
Piero Olliaro
Nipah virus disease is a bat-borne zoonosis with person-to-person transmission, a case fatality rate of 38-75%, and recognised pandemic potential. The first reported outbreak occurred in Malaysia and Singapore in 1998, since followed by multiple outbreaks in Bangladesh and India. No therapeutics or vaccines have been licensed to date, and only few candidates are in development. This systematic review aimed to assess the evidence for the safety and efficacy of therapeutic options (monoclonal antibodies and small molecules) for Nipah virus and other henipaviral diseases in order to support candidate prioritisation for further evaluation in clinical trials. At present, there is sufficient evidence to trial only m102.4 and remdesivir (singly and/or in combination) for prophylaxis and early treatment of Nipah virus disease. In addition to well-designed clinical efficacy trials, in vivo pharmacokinetic-pharmacodynamic studies to optimise selection and dosing of therapeutic candidates in animal challenge and natural human infection are needed. Research in context: Evidence before this study: Nipah virus infection is a bat-borne zoonosis with person-to-person transmission, a case fatality rate of 38-75%, and recognised pandemic potential. No therapeutics or vaccines have been licensed to date, and only few candidates are in development. We conducted this systematic review to assess the evidence for the safety and efficacy of therapeutic options (monoclonal antibodies and small molecules) for Nipah virus and other henipaviral diseases to support candidate prioritisation for further evaluation in clinical trials. We searched bibliographic databases for journal articles, conference abstracts, and patents: PubMed, Ovid Embase, Ovid CAB Abstracts, Ovid Global Health, Scopus, Web of Science (all databases), and the WHO Global Index Medicus. “Henipavirus” or “Nipah” or “Hendra” along with “therapeutics” or “monoclonal” were the title, abstract, and subject heading keywords, with synonyms and variant spellings as additional search terms. We searched trial registries for clinical trials of Henipavirus, Nipah virus, and Hendra virus at all stages of recruitment: Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform. We searched the Trip database and WHO website for guidelines and reports. All searches were conducted on 30 May 2022. We did not apply language or publication date limits. Studies were included if they contained primary data on the safety and/or efficacy of monoclonal antibodies ( in vivo) or small molecules ( in vivo or in vitro ) for the treatment and/or prophylaxis of Nipah, Hendra, and related Henipaviridae . Almost all had critical or high risk of bias. Added value of this study: This is the most detailed systematic review and analysis of the Nipah virus therapeutics landscape to date, including all available in vivo and related in vitro data on the safety, efficacy, and pharmaco-kinetics of monoclonal antibodies and small molecules with the specific aim of supporting prioritisation for clinical trials. We also present a roadmap for how in vivo development of Nipah therapeutics could be strengthened to achieve greater equity, efficiency, and effectiveness. Implications of the available evidence: At present, there is sufficient evidence to trial only m102.4 and remdesivir for prophylaxis and early treatment of Nipah virus infection. Well-designed clinical efficacy trials as well as in vivo pharmacokinetic-pharmacodynamic studies to optimise selection and dosing of therapeutic candidates in animal challenge and natural human infection are needed.

26 October 2023 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
SLShanghavie Loganathan
Shanghavie Loganathan
SSSarah Louise Smyth
Sarah Louise Smyth
RMRoman Mykula
Roman Mykula
HMHooman Soleymani majd
Hooman Soleymani majd
Chronic, severe Crohn's disease in a young female patient can result in surgical complexity. The rarity of the presentation of intractable pelvic abscesses within this etiology with additional considerations given to fertility concerns and hence requirement for input from a multi‐disciplinary team makes this a vital case in building a consensus for evidence‐based surgical management. A 29‐year‐old nulliparous woman was referred to our tertiary centre for surgical management of Crohn's disease with known tubo‐ovarian abscess and abdominoperineal and abdominal wall sinuses. Her previous surgical history included 4 midline laparotomies, subtotal colectomy and proctectomy with stoma formation. The patient underwent egg collection to preserve fertility. This was followed by midline laparotomy and abdominoperineal resection, which involved a retrograde radical modified hysterectomy using the Hudson technique, alongside excision of the perineal sinus, with reconstruction of the perineal defect using an internal pudendal artery perforator gluteal fold flap, and in addition to excision and drainage of the abdominal wall abscess. Involvement was sought from gynecological oncology, colorectal, urology, plastics, stoma, fertility, microbiology, and gastroenterology teams, which enabled successful preservation of end organ function and improvement in patient psychological well‐being. This case is a paradigm of surgical challenge, requiring expert gynecological oncology techniques including a retroperitoneal approach, nerve and vessel sparing considerations alongside colorectal and urological procedures. Moreover, we believe that our blueprint for effective multi‐disciplinary practice will inform the future management of gynecological surgery. Therefore this report aims to contribute towards the optimum management of the gynecological sequelae of Crohn's disease.

30 September 2021
Verified
Conference Paper
Open access
PDF file
SLShanghavie Loganathan
Shanghavie Loganathan
EQEsther Quinn
Esther Quinn
SRSahana Rao
Sahana Rao
Background Effective communication is key to providing safe, high-quality clinical care. Evidence shows that in higher income countries where English is the primary language, patients with limited English proficiency have poorer clinical outcomes and compromised patient care. As the provision of equitable, patient-centred care requires active engagement with the consultation, we posit that the use of professional interpreters within this cohort would improve clinical outcomes. Informal feedback and experience within our trust suggested that the use of interpretation services was limited and improving provision could improve patient care. Objectives We undertook a quality improvement (QI) project to improve the use of interpretation services in paediatrics. We set out to identify obstacles to the utilisation of services and suitable methods that would overcome them. Methods The initial survey was conducted in 2020 and explored the use of services and barriers. A multitude of reasons for low uptake were identified, including lack of clarity over access details, time constraints and the lack of appropriate equipment. We instituted changes based on this survey, including providing information on interpretation services. This was in the format of posters, emails, and educational sessions. The access codes and contact details required were made easily available and accessible to medical staff, nursing staff and allied health professionals. Definitive guidelines for use of interpretation services and appropriate access to phones with the necessary speaker function were also provided. Results As part of the survey 19 questionnaires were completed, with 80% being completed by doctors and 20% by nurses. 100% of respondents identified situations where they felt interpretation would have been useful. Despite this, only 63% had used the service. Furthermore, only 16% used the service as part of their routine practice. This project was discussed and approved at the paediatric clinical governance meeting. Subsequent to our intervention in April 2020, we identified an increase in usage of interpretation services as highlighted in the table below. The project was supported by a trust-wide QI programme and after presentation to senior management and patient experience teams, we were able to focus on its incorporation into induction programmes. Finally, we were also able to promote the use of interpreters at regional paediatric meetings. During the COVID pandemic, there was a shift towards remote working and virtual clinics which required adaptation of our guidelines and systems. This information was also disseminated throughout the department but a repeat survey had to be postponed due to trainee redeployment during the COVID pandemic. Conclusions Staff identified that interpretation services were beneficial to their clinical practice and patients, but there was a perceived lack of support and resources. We addressed this by improving awareness, providing education and increasing access for all members of the multi-disciplinary team. We recognise that only continuous education and structural implementation of interpretation systems at an organisational level, can allow sustainable implementation of this model.

20 January 2025 in InnovAiT: Education and Inspiration for General Practice
Verified
Journal Article
Closed access
SLShanghavie Loganathan
Shanghavie Loganathan
JMJo Middleton
Jo Middleton
JHJason Heath
Jason Heath
MCMaxwell Cooper
Maxwell Cooper
Travel medicine is a medical specialty focusing on the prevention and treatment of health issues before, during and after international travel. Services typically include pre-travel advice, vaccinations, prescription medications and post-travel care. Provision of many travel services falls outside NHS funding and is increasingly provided privately by pharmacies and travel clinics. General practice is a first point of contact for some travellers offering an opportunity for GPs to provide advice or to signpost if appropriate to dedicated travel health services. This article will cover travel medicine and use of brief interventions to motivate engagement of patients in behaviour change opportunistically when seeking travel advice.

16 February 2025 in Journal of Medical Biography
Verified
Journal Article
Open access
SLShanghavie Loganathan
Shanghavie Loganathan
MCMax Cooper
Max Cooper
Francis Home (1719–1813) was a Scottish physician and medical author. Here we consider his biography and three brief accounts of experiments on viper (i.e. adder flesh) broth in the treatment of skin disease (‘Herpes or Lepra Gracaeorum’). After a fortnight of treatment one patient was improved but not cured (discontinued due to lack of vipers), one ‘almost cured’ but refused further treatment at ‘disgust’ of discovering its contents, and one dismissed cured. The second case constitutes a basic ‘cross-over’ model as it led to comparison of viper with snail broth in the same patient. Home concluded that viper broth was beneficial for skin disease but his findings did not lead to wider adoption of the treatment. His reported clinical benefits likely arose from improved hydration, protein and cessation of other treatments. Home does not discuss his small sample size or present quantitative outcomes. Home's methods were not influenced by Lind's (1753) methodology for comparing treatments. As both were Edinburgh-trained Scots who served in the British military forces, this reveals the limited communication between clinicians of the day. Home appears to have faced many practical challenges, including accessing vipers, motivating patients’ participation and the risk of concomitant treatment with other drugs.